Loading…
Double‐blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2‐receptor antagonists
Background : Maintenance antisecretory therapy is often used to prevent duodenal ulcer recurrence and control symptoms. This study compared the efficacy and safety of lansoprazole 15 mg and 30 mg daily with placebo in preventing ulcer recurrence in patients with a recent history of duodenal ulcer di...
Saved in:
| Published in: | Alimentary pharmacology & therapeutics 1999-07, Vol.13 (7), p.959-967 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 967 |
| container_issue | 7 |
| container_start_page | 959 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 13 |
| creator | KOVACS, T. O. G CAMPBELL, D RICHTER, J HABER, M JENNINGS, D. E ROSE, P |
| description | Background
: Maintenance antisecretory therapy is often used to prevent duodenal ulcer recurrence and control symptoms. This study compared the efficacy and safety of lansoprazole 15 mg and 30 mg daily with placebo in preventing ulcer recurrence in patients with a recent history of duodenal ulcer disease.
Methods
: Fifty‐six patients were treated with either lansoprazole 15 mg, 30 mg or placebo o.m.
Results
: Within 1 month of study initiation, 27% (four out of 15) of placebo‐treated patients experienced ulcer recurrence as compared to 13% (two out of 15) and 6% (one out of 18) of lansoprazole 15 mg and 30 mg treated patients, respectively. Median time to first ulcer recurrence was > 12 months in lansoprazole patients. At Month 12, significantly (P |
| doi_str_mv | 10.1046/j.1365-2036.1999.00569.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69853137</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69853137</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1869-75ab5eb96a60961bf49fffe27c7e9559c4d0079dc18ac5f7a65591506feee67d3</originalsourceid><addsrcrecordid>eNpVkc1u1DAUhSMEokPhFZAXiBUT7HjsxBKbqvwUqRIsytq6cW46HjlxsB21w6oSL8Dr8Dp9Epx2-FvZOvfzsX1OURBGS0Y38vWuZFyKdUW5LJlSqqRUSFVePyhWfwYPixWtpFpXDeNHxZMYd5RSWdPqcXHEKG-44NWq-PnWz63D25sfrbNjR4wfJgg2-pH4njgYo58CfPMOCRO3N9-Hy1f_q5zeqQTy4cmBwdYTiGQAOyYcYTRI0hYDTHtiRzJBsjimSK5s2pItgsOOdLPvMurI7AyGSAJGGxOMiSRPzqr8toAGp-RDviXBpR_zOD4tHvXgIj47rMfFl_fvLk7P1uefPnw8PTlfT6zJ368FtAJbJUFSJVnbb1Tf91jVpkYlhDKbjtJadYY1YERfg8wiE1T2iCjrjh8XL-99p-C_zhiTHmw06HIK6OeopWoEZ7zO4PMDOLcDdnoKdoCw17_DzsCLAwDRgOtDTsfGv1z2kXTxeXOPXVmH-39s9NK93umlYr1UrJfu9V33-lqffL7IG_4L3_up7g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69853137</pqid></control><display><type>article</type><title>Double‐blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2‐receptor antagonists</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>KOVACS, T. O. G ; CAMPBELL, D ; RICHTER, J ; HABER, M ; JENNINGS, D. E ; ROSE, P</creator><creatorcontrib>KOVACS, T. O. G ; CAMPBELL, D ; RICHTER, J ; HABER, M ; JENNINGS, D. E ; ROSE, P</creatorcontrib><description>Background
: Maintenance antisecretory therapy is often used to prevent duodenal ulcer recurrence and control symptoms. This study compared the efficacy and safety of lansoprazole 15 mg and 30 mg daily with placebo in preventing ulcer recurrence in patients with a recent history of duodenal ulcer disease.
Methods
: Fifty‐six patients were treated with either lansoprazole 15 mg, 30 mg or placebo o.m.
Results
: Within 1 month of study initiation, 27% (four out of 15) of placebo‐treated patients experienced ulcer recurrence as compared to 13% (two out of 15) and 6% (one out of 18) of lansoprazole 15 mg and 30 mg treated patients, respectively. Median time to first ulcer recurrence was > 12 months in lansoprazole patients. At Month 12, significantly (P < 0.001) more lansoprazole 15 mg patients (70%) and lansoprazole 30 mg patients (85%) remained healed. Eighty‐two per cent of lansoprazole 15 mg and 76% of lansoprazole 30 mg patients remained asymptomatic during the entire study period. All placebo patients became symptomatic, experienced ulcer recurrence, or withdrew from the study by month six. The incidence of adverse events was comparable among the three treatment groups.
Conclusions
: Lansoprazole safely and effectively reduces duodenal ulcer recurrence and ulcer‐related symptoms.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1046/j.1365-2036.1999.00569.x</identifier><identifier>PMID: 10383532</identifier><language>eng</language><publisher>Oxford UK: Blackwell Science Ltd</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles ; Adult ; Aged ; Anti-Ulcer Agents - administration & dosage ; Biological and medical sciences ; Digestive system ; Double-Blind Method ; Drug Resistance ; Duodenal Ulcer - metabolism ; Duodenal Ulcer - prevention & control ; Female ; Gastric Mucosa - metabolism ; Gastrins - blood ; Histamine H2 Antagonists - pharmacology ; Humans ; Lansoprazole ; Male ; Medical sciences ; Middle Aged ; Omeprazole - administration & dosage ; Omeprazole - analogs & derivatives ; Pharmacology. Drug treatments ; Proton Pump Inhibitors ; Recurrence ; Treatment Outcome ; United States</subject><ispartof>Alimentary pharmacology & therapeutics, 1999-07, Vol.13 (7), p.959-967</ispartof><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1853607$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10383532$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KOVACS, T. O. G</creatorcontrib><creatorcontrib>CAMPBELL, D</creatorcontrib><creatorcontrib>RICHTER, J</creatorcontrib><creatorcontrib>HABER, M</creatorcontrib><creatorcontrib>JENNINGS, D. E</creatorcontrib><creatorcontrib>ROSE, P</creatorcontrib><title>Double‐blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2‐receptor antagonists</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Background
: Maintenance antisecretory therapy is often used to prevent duodenal ulcer recurrence and control symptoms. This study compared the efficacy and safety of lansoprazole 15 mg and 30 mg daily with placebo in preventing ulcer recurrence in patients with a recent history of duodenal ulcer disease.
Methods
: Fifty‐six patients were treated with either lansoprazole 15 mg, 30 mg or placebo o.m.
Results
: Within 1 month of study initiation, 27% (four out of 15) of placebo‐treated patients experienced ulcer recurrence as compared to 13% (two out of 15) and 6% (one out of 18) of lansoprazole 15 mg and 30 mg treated patients, respectively. Median time to first ulcer recurrence was > 12 months in lansoprazole patients. At Month 12, significantly (P < 0.001) more lansoprazole 15 mg patients (70%) and lansoprazole 30 mg patients (85%) remained healed. Eighty‐two per cent of lansoprazole 15 mg and 76% of lansoprazole 30 mg patients remained asymptomatic during the entire study period. All placebo patients became symptomatic, experienced ulcer recurrence, or withdrew from the study by month six. The incidence of adverse events was comparable among the three treatment groups.
Conclusions
: Lansoprazole safely and effectively reduces duodenal ulcer recurrence and ulcer‐related symptoms.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Ulcer Agents - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Digestive system</subject><subject>Double-Blind Method</subject><subject>Drug Resistance</subject><subject>Duodenal Ulcer - metabolism</subject><subject>Duodenal Ulcer - prevention & control</subject><subject>Female</subject><subject>Gastric Mucosa - metabolism</subject><subject>Gastrins - blood</subject><subject>Histamine H2 Antagonists - pharmacology</subject><subject>Humans</subject><subject>Lansoprazole</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Omeprazole - administration & dosage</subject><subject>Omeprazole - analogs & derivatives</subject><subject>Pharmacology. Drug treatments</subject><subject>Proton Pump Inhibitors</subject><subject>Recurrence</subject><subject>Treatment Outcome</subject><subject>United States</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNpVkc1u1DAUhSMEokPhFZAXiBUT7HjsxBKbqvwUqRIsytq6cW46HjlxsB21w6oSL8Dr8Dp9Epx2-FvZOvfzsX1OURBGS0Y38vWuZFyKdUW5LJlSqqRUSFVePyhWfwYPixWtpFpXDeNHxZMYd5RSWdPqcXHEKG-44NWq-PnWz63D25sfrbNjR4wfJgg2-pH4njgYo58CfPMOCRO3N9-Hy1f_q5zeqQTy4cmBwdYTiGQAOyYcYTRI0hYDTHtiRzJBsjimSK5s2pItgsOOdLPvMurI7AyGSAJGGxOMiSRPzqr8toAGp-RDviXBpR_zOD4tHvXgIj47rMfFl_fvLk7P1uefPnw8PTlfT6zJ368FtAJbJUFSJVnbb1Tf91jVpkYlhDKbjtJadYY1YERfg8wiE1T2iCjrjh8XL-99p-C_zhiTHmw06HIK6OeopWoEZ7zO4PMDOLcDdnoKdoCw17_DzsCLAwDRgOtDTsfGv1z2kXTxeXOPXVmH-39s9NK93umlYr1UrJfu9V33-lqffL7IG_4L3_up7g</recordid><startdate>199907</startdate><enddate>199907</enddate><creator>KOVACS, T. O. G</creator><creator>CAMPBELL, D</creator><creator>RICHTER, J</creator><creator>HABER, M</creator><creator>JENNINGS, D. E</creator><creator>ROSE, P</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>199907</creationdate><title>Double‐blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2‐receptor antagonists</title><author>KOVACS, T. O. G ; CAMPBELL, D ; RICHTER, J ; HABER, M ; JENNINGS, D. E ; ROSE, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1869-75ab5eb96a60961bf49fffe27c7e9559c4d0079dc18ac5f7a65591506feee67d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Ulcer Agents - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Digestive system</topic><topic>Double-Blind Method</topic><topic>Drug Resistance</topic><topic>Duodenal Ulcer - metabolism</topic><topic>Duodenal Ulcer - prevention & control</topic><topic>Female</topic><topic>Gastric Mucosa - metabolism</topic><topic>Gastrins - blood</topic><topic>Histamine H2 Antagonists - pharmacology</topic><topic>Humans</topic><topic>Lansoprazole</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Omeprazole - administration & dosage</topic><topic>Omeprazole - analogs & derivatives</topic><topic>Pharmacology. Drug treatments</topic><topic>Proton Pump Inhibitors</topic><topic>Recurrence</topic><topic>Treatment Outcome</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KOVACS, T. O. G</creatorcontrib><creatorcontrib>CAMPBELL, D</creatorcontrib><creatorcontrib>RICHTER, J</creatorcontrib><creatorcontrib>HABER, M</creatorcontrib><creatorcontrib>JENNINGS, D. E</creatorcontrib><creatorcontrib>ROSE, P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KOVACS, T. O. G</au><au>CAMPBELL, D</au><au>RICHTER, J</au><au>HABER, M</au><au>JENNINGS, D. E</au><au>ROSE, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Double‐blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2‐receptor antagonists</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>1999-07</date><risdate>1999</risdate><volume>13</volume><issue>7</issue><spage>959</spage><epage>967</epage><pages>959-967</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Background
: Maintenance antisecretory therapy is often used to prevent duodenal ulcer recurrence and control symptoms. This study compared the efficacy and safety of lansoprazole 15 mg and 30 mg daily with placebo in preventing ulcer recurrence in patients with a recent history of duodenal ulcer disease.
Methods
: Fifty‐six patients were treated with either lansoprazole 15 mg, 30 mg or placebo o.m.
Results
: Within 1 month of study initiation, 27% (four out of 15) of placebo‐treated patients experienced ulcer recurrence as compared to 13% (two out of 15) and 6% (one out of 18) of lansoprazole 15 mg and 30 mg treated patients, respectively. Median time to first ulcer recurrence was > 12 months in lansoprazole patients. At Month 12, significantly (P < 0.001) more lansoprazole 15 mg patients (70%) and lansoprazole 30 mg patients (85%) remained healed. Eighty‐two per cent of lansoprazole 15 mg and 76% of lansoprazole 30 mg patients remained asymptomatic during the entire study period. All placebo patients became symptomatic, experienced ulcer recurrence, or withdrew from the study by month six. The incidence of adverse events was comparable among the three treatment groups.
Conclusions
: Lansoprazole safely and effectively reduces duodenal ulcer recurrence and ulcer‐related symptoms.</abstract><cop>Oxford UK</cop><pub>Blackwell Science Ltd</pub><pmid>10383532</pmid><doi>10.1046/j.1365-2036.1999.00569.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 1999-07, Vol.13 (7), p.959-967 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69853137 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | 2-Pyridinylmethylsulfinylbenzimidazoles Adult Aged Anti-Ulcer Agents - administration & dosage Biological and medical sciences Digestive system Double-Blind Method Drug Resistance Duodenal Ulcer - metabolism Duodenal Ulcer - prevention & control Female Gastric Mucosa - metabolism Gastrins - blood Histamine H2 Antagonists - pharmacology Humans Lansoprazole Male Medical sciences Middle Aged Omeprazole - administration & dosage Omeprazole - analogs & derivatives Pharmacology. Drug treatments Proton Pump Inhibitors Recurrence Treatment Outcome United States |
| title | Double‐blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2‐receptor antagonists |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T20%3A43%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Double%E2%80%90blind%20comparison%20of%20lansoprazole%2015%E2%80%83mg,%20lansoprazole%2030%E2%80%83mg%20and%20placebo%20as%20maintenance%20therapy%20in%20patients%20with%20healed%20duodenal%20ulcers%20resistant%20to%20H2%E2%80%90receptor%20antagonists&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=KOVACS,%20T.%20O.%20G&rft.date=1999-07&rft.volume=13&rft.issue=7&rft.spage=959&rft.epage=967&rft.pages=959-967&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1046/j.1365-2036.1999.00569.x&rft_dat=%3Cproquest_pubme%3E69853137%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p1869-75ab5eb96a60961bf49fffe27c7e9559c4d0079dc18ac5f7a65591506feee67d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69853137&rft_id=info:pmid/10383532&rfr_iscdi=true |